Get the Stockscreener App
35.53
4.60%
-1.7105
Bright Minds Biosciences Inc stock is traded at $35.53, with a volume of 53,278.
It is down -4.60% in the last 24 hours and down -4.62% over the past month.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$37.24
Open:
$37
24h Volume:
53,278
Relative Volume:
0.53
Market Cap:
$256.54M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-26.96
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
-1.14%
1M Performance:
-4.62%
6M Performance:
+3,175%
1Y Performance:
+1,919%
1-Day Range:
$35.43
$37.00
1-Week Range:
$32.78
$37.54
52-Week Range:
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
35.72 | 256.54M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.02 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.15 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.08 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March - The Manila Times
How the (DRUG) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Issues Negative Estimate for DRUG Earnings - Defense World
H.C. Wainwright maintains $85 target on Bright Minds stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains $85 target on Bright Minds stock - Investing.com India
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences’ BMB-101: A Promising Contender in Serotonergic Epilepsy Treatment with Strong Market Potential - TipRanks
Bright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPS - MarketBeat
Bright Minds Biosciences Dramatic Surge Highlights the High-Stakes Nature of Biotech Investments - HPBL
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - Benzinga
Bright Minds Biosciences Shows Financial Improvement in Latest Report - TipRanks
When (DRUG) Moves Investors should Listen - Stock Traders Daily
SEC Form F-3 filed by Bright Minds Biosciences Inc. - Quantisnow
More Money In The Bank For Bright Minds Biosciences Insiders Who Divested CA$16m - Simply Wall St
How To Buy Bright Minds Biosciences Inc. Stock Online in February 2025 - Traders Union
Long Term Trading Analysis for (DRUG) - Stock Traders Daily
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Bright Minds Biosciences Appoints Stephen Collins, M.D., Ph.D., as Chief Medical Officer - citybiz
Bright Minds Biosciences (NASDAQ:DRUG) Releases Earnings Results - MarketBeat
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq
(DRUG) Long Term Investment Analysis - Stock Traders Daily
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% – Time to Sell? - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3%Time to Sell? - MarketBeat
(DRUG) Investment Analysis - Stock Traders Daily
Retail investors among Bright Minds Biosciences Inc.'s (CSE:DRUG) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Baird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform Recommendation - MSN
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Strong-Buy" at Baird R W - MarketBeat
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bright Minds Biosciences Inc Stock (DRUG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 10% Owner |
Oct 15 '24 |
Buy |
5.53 |
372,591 |
2,061,574 |
825,000 |
| Cormorant Asset Management, LP | 10% Owner |
Oct 16 '24 |
Buy |
23.46 |
50,000 |
1,172,813 |
875,000 |
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):